Sphingosine-1-phosphate receptor agonist, process for its preparation and pharmaceutical composition comprising same as active agent

A compound, C1-C6 technology, applied in the direction of drug combination, organic active ingredients, antipyretics, etc., can solve the problem of decreased infiltration of autoimmune lymphocytes, etc.

Active Publication Date: 2018-05-18
LG CHEM LTD
View PDF33 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, if S1P1 receptors in lymphocytes are downregulated by S1P1 agonists, lymphocytes do not leave lymphoid tissue, resulting in a reduced infiltration of autoimmune lymphocytes that lead to central nervous system (CNS) inflammation and tissue damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sphingosine-1-phosphate receptor agonist, process for its preparation and pharmaceutical composition comprising same as active agent
  • Sphingosine-1-phosphate receptor agonist, process for its preparation and pharmaceutical composition comprising same as active agent
  • Sphingosine-1-phosphate receptor agonist, process for its preparation and pharmaceutical composition comprising same as active agent

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1-1

[0328] Preparation 1-1: Synthesis of methyl 1-isopropyl-1H-indole-5-carboxylate

[0329] At 0°C, 1H-indole-5-carboxylic acid methyl ester (1g, 5.71mmol) was dissolved in dimethylformamide (20mL), and isopropyl iodide (1.14mL, 11.42mmol ) and sodium hydride (205 mg, 8.56 mmol). The mixture was stirred at 50°C for 8 hours, 1N hydrochloric acid solution was added, and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was distilled under reduced pressure and separated by column chromatography to obtain the title compound (1.1 g, 89%).

[0330] NMR: 1H-NMR (400HMz, CDCl 3 ); 3H), 1.54(d, 6H)

preparation example 1-2

[0331] Preparation 1-2: Synthesis of 1-isopropyl-1H-indole-5-carboxylic acid

[0332] The compound (1.1 g, 5.06 mmol) obtained from Preparation Example 1-1 was dissolved in a mixed solution of tetrahydrofuran and methanol (2 / 1, 20 mL), and 1N aqueous sodium hydroxide solution (10 mL, 10.12 mmol) was slowly added dropwise thereto . The mixture was stirred at room temperature for 18 hours, 1N hydrochloric acid solution was added, and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was distilled under reduced pressure to obtain the title compound (900 mg, 88%).

[0333] NMR: 1H-NMR (400HMz, CDCl 3 ); 6H)

preparation example 1-3

[0334] Preparation Example 1-3: Synthesis of 3-[4-(N-hydroxyformamidoyl (carbimidoyl))-3-methyl-phenyl]-propionic acid ethyl ester

[0335] The title compound was obtained by the method described in EP 2202232.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to novel compounds of formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used in the treatment of autoimmune diseases, processes for the preparation of said compounds and comprising said compounds as active ingredients pharmaceutical composition. The compounds of the invention are effective against a wide range of autoimmune and chronic inflammatory diseases, including relapsing remitting multiple sclerosis, and can be used to treat or prevent immunomodulatory disorders.

Description

technical field [0001] The present invention relates to novel compounds which are agonists of the sphingosine-1-phosphate receptor, which can be effectively used in the treatment of autoimmune diseases such as multiple sclerosis, and to processes for the preparation of said compounds and to compounds comprising said compounds as Pharmaceutical composition of active ingredients. Background technique [0002] S1P (sphingosine-1-phosphate) is produced via the intracellular ceramide pathway with ceramide as the starting material. Ceramides are produced via two pathways, the first being the de novo biosynthetic pathway. Ceramides are also produced in cells by the degradation of the cell membrane component sphingomyelin. S1P levels in each tissue are controlled by two biosynthetic sphingosine kinases (SphK) and two biodegradable S1P phosphatases (S1P lyase and lysophospholipid phosphatase). SlP, produced by phosphorylation of sphingosine by sphingosine kinase, is known to media...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D413/04C07D271/12A61K31/4245A61P37/00
CPCC07D209/08C07D209/30C07D231/56C07D401/12C07D403/12C07D413/04C07D413/14C07D471/04A61P1/04A61P1/16A61P17/00A61P17/02A61P19/02A61P21/00A61P25/00A61P29/00A61P37/00A61P37/06A61P43/00A61P9/10A61K31/4245
Inventor 白承烨李成培朴德星李沅炯
Owner LG CHEM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap